Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CBMG

Cellular Biomedicine Group (CBMG) Stock Price, News & Analysis

Cellular Biomedicine Group logo

About Cellular Biomedicine Group Stock (NASDAQ:CBMG)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$17.67
$19.75
52-Week Range
N/A
Volume
8,375 shs
Average Volume
129,776 shs
Market Capitalization
$384.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CBMG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellular Biomedicine Group and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CBMG Stock News Headlines

Buffett, Gates and Bezos Dumping Stocks
The world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t see in America for more than a century.tc pixel
See More Headlines

CBMG Stock Analysis - Frequently Asked Questions

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) posted its earnings results on Monday, November, 9th. The biotechnology company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by $0.25. The biotechnology company had revenue of $0.03 million for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cellular Biomedicine Group investors own include CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), Aduro Biotech (ADRO), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Bristol Myers Squibb (BMY) and Intellia Therapeutics (NTLA).

Company Calendar

Last Earnings
11/09/2020
Today
9/13/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CBMG
CIK
1378624
Fax
N/A
Employees
217
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$49.98 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-144.80%
Return on Assets
-61.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.47
Quick Ratio
0.47

Sales & Book Value

Annual Sales
$340 thousand
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.89 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
19,478,000
Free Float
N/A
Market Cap
$384.69 million
Optionable
Optionable
Beta
1.35
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:CBMG) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners